Genmab — Juni 2019
-
DARA + pom-dex for R/R multiple myeloma / Sagar Lonial
https://www.youtube.com/watch?v=ptOIpHrBEfI -
bb2121 nu også i NEJM: The median time to disease worsening or death was 11.8 months. https://myelomaresearchnews.com/2019/06/03/car-t-cell-candidate-bb2121-shows-promising-safety-efficacy-relapsed-refractory-myeloma-interim-data/
-
Pensionist 15.21/22. Der skal ikke meget til at gøre dig usikker. Faktum er vi ikke ved hvad der ligger bag ansøgningen og Genmabkolder selvfølgelig kortene tæt til kroppen. Jan kan ikke sige at de er ved at lave en 50/50 deal med JNJ men at JNJ har krævet Genmak har finanseringen iorden.
-
for m ig giverr det stadig aaaaabsolut nada mening at skulle hente 3 mia fordi de laver en 50/50 aftale. De 2 stoffer er stadig på så tidligt et stadie at der allivel max vil blive startet forsøg op med 2000 patienter over de næste 2 år hvilket vil koste ca 2 mia dkk. Og Genmab vil få $50-100 mio upfront per stk pluse milestones der vil betale det meste af udvikliongen frem til "fase 4" forsøgene starter. Det er først der det for ALVOR bliver dyrt. Janssen har f.eks pt gang i
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
Pensionisten
